Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research

By David Holley, Xconomy San Antonio—A small Texas biotech that develops women’s health ...

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Ricardo Carrion, Jr., Ph.D. During the West African Ebola outbreak that began in 2013, an experimental ...

Biotech firm GenSpera completes another funding round
May 2, 2011

San Antonio Business Journal - by Tamarind Phinisee

GenSpera Inc. recently raised $2.2 million to help advance research into a promising cancer-treatment drug.
The securities sold during the private placement were priced at $1.65 per unit - with each unit consisting of one share of common stock and a half common stock purchase warrant.

Craig Dionne, Ph.D., GenSpera CEO and president, says the offering brings the total funds raised by the firm this year to about $6.2 million.

"The monies raised in January and February assured funding for an aggressive Phase II clinical program for our lead drug G-202, currently in a FDA-approved Phase I safety trial," Dionne says. "This current financing provides funds for the full pre-clinical development of G-115, our second drug, specifically targeted for prostate cancer."

San Antonio-based GenSpera (OTCBB: GNSZ) is conducting Phase 1 clinical trials at the Cancer Therapy Research Center in San Antonio, Johns Hopkins University in Baltimore and the University of Wisconsin Carbone Cancer Center in Madison.


Stay informed. Subscribe to BioMed SA news alerts.